Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma Journal Article


Authors: Furqan, F.; Ahn, K. W.; Chen, Y.; Kaur, M.; Abutalib, S. A.; Ahmed, N.; Ahmed, S.; Kharfan-Dabaja, M. A.; Friedberg, J.; Gregory, T.; Hill, L.; Sterling, C.; Barta, S. K.; Shadman, M.; Perales, M. A.; Zain, J.; Herrera, A. F.; Sauter, C.; Hamadani, M.
Article Title: Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma
Abstract: The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes of allogeneic haematopoietic cell transplantation (allo-HCT) in systemic R/R ALCL are not available. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we evaluated outcomes of 182 adults (aged ≥18 years) with R/R ALCL undergoing allo-HCT between 2008 and 2019. Non-relapse mortality (NRM), disease relapse/progression (REL), progression-free survival (PFS), and overall survival (OS) were modelled using Cox proportional hazards models. The median (range) follow-up of survivors was 62 (3–148) months. The 1-year NRM was 18%. The 5-year REL, PFS and OS were 32%, 41% and 56% respectively. On multivariable regression analysis African American race (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.6–4.8; p < 0.001) and refractory disease at allo-HCT (HR 3.2, 95% CI 1.6–6.2; p < 0.001) were predictive of inferior OS. Similarly, African-American race (HR 2.1, 95% CI 1.3–3.4; p = 0.003), other minority race (HR 2.5, 95% CI 1.2–5.3; p = 0.02) and refractory disease (HR 2.2, 95% CI 1.2–4.3; p = 0.01) were predictive of inferior PFS. These data, demonstrate that allo-HCT can result in durable disease control in a sizable proportion of patients with R/R ALCL. Refractory disease and racial minority status predicted inferior allo-HCT outcomes. Whether the inferior outcomes of racial minorities with R/R ALCL after allo-HCT are driven by differences in disease biology or disparities in post allo-HCT care, or both, requires further investigation. © 2022 British Society for Haematology and John Wiley & Sons Ltd.
Keywords: adolescent; adult; retrospective studies; neoplasm recurrence, local; hematopoietic stem cell transplantation; retrospective study; chronic disease; tumor recurrence; graft versus host reaction; transplantation conditioning; graft vs host disease; progression-free survival; allogeneic transplantation; lymphoma, large-cell, anaplastic; graft-versus-host disease; anaplastic large cell lymphoma; humans; prognosis; human; graft versus leukaemia
Journal Title: British Journal of Haematology
Volume: 200
Issue: 1
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2023-01-01
Start Page: 54
End Page: 63
Language: English
DOI: 10.1111/bjh.18467
PUBMED: 36120837
PROVIDER: scopus
PMCID: PMC9772096
DOI/URL:
Notes: Article -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Miguel-Angel Perales
    918 Perales